Src tyrosine kinase regulates CYP17 expression and androstenedione secretion in theca-enriched mouse ovarian cells

Gaurav Chaturvedi1, Koji Arai, Darlene Limback

  • 1Department of Molecular and Integrative Physiology, The Center for Reproductive Sciences, Kansas University Medical Center, Kansas City, KS 66160, USA.

Endocrine
|February 16, 2005
PubMed

Insights

Src tyrosine kinase inhibitors increased androstenedione secretion in mouse ovarian theca-enriched cells. This effect may involve protein kinase A, suggesting a role for Src in thecal cell steroidogenesis.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Cell Biology

Background:

  • Src tyrosine kinase is implicated in G protein-coupled receptor signaling.
  • Luteinizing hormone (LH) stimulates ovarian thecal cells to increase steroidogenesis via cAMP and protein kinase A (PKA).

Purpose of the Study:

  • To investigate the role of Src tyrosine kinase in the regulation of steroidogenesis in mouse ovarian theca-enriched cells (TEC).

Main Methods:

  • TEC were treated in vitro with Src inhibitors geldanamycin (GA) and herbimycin A (HA).
  • Androstenedione secretion, cAMP levels, and cytochrome P450 17alpha-hydroxylase/lyase (CYP17) mRNA expression were analyzed.
  • CYP17 promoter activity was assessed, and the effect of PKA inhibition was evaluated.

Main Results:

  • GA and HA treatment increased basal androstenedione secretion without altering cAMP levels.
  • Both inhibitors enhanced androstenedione secretion in the presence of forskolin.
  • GA treatment increased CYP17 mRNA expression and promoter activity.
  • PKA inhibition blocked the effect of GA and HA on androstenedione secretion.

Conclusions:

  • Pharmacological inhibition of Src increases thecal cell CYP17 promoter activity, CYP17 mRNA, and androstenedione secretion.
  • The observed increase in androstenedione secretion is potentially cAMP-independent but requires PKA activity.